Clinical Trial Update: Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating an extended-release formulation of rosiglitazone (RSG XR) in mild Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Rosiglitazone XR (rosiglitazone extended-release)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED